Infectious Disease Control
CGTN: China protects lives, shares experience in global COVID-19 fight
BEIJING, Jan. 16, 2023 /PRNewswire/ -- Chinese people are embracing a bustling winter after the country downgraded its COVID-19 management policies. It's a breakthrough in the country's three-year fight against the pandemic, but challenges still lie ahead. Along the journey, China went all out...
CGTN: TCM continues to play significant role in treating COVID-19
BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role inChina's fight against COVID-19. As China is shifting the focus of its COVID-19 response from preventing infections to protecting people's health and preventing severe cases, the unique...
CGTN: China downgrades COVID-19 rules as nation readies for normal life
BEIJING, Jan. 9, 2023 /PRNewswire/ -- China put its downgraded COVID-19
measures into force on Sunday as the nation began to resume normal life after
three years of strict pandemic management.
China welcomes first arrivals following downgraded COVID management
BEIJING, Jan. 9, 2023 /PRNewswire/ -- A report from People's Daily: The first flights underChina's new COVID-19 management for international travelers arrived at airports in southChina's Guangdong province on Jan. 8, according to the national customs authority. Over 380 passengers were aboard tw...
CGTN: China's preparedness for adjusting its COVID-19 policies
BEIJING, Jan. 5, 2023 /PRNewswire/ -- Since China prioritized its COVID-19
response from the dynamic zero-COVID policy, some Western media and
intellectuals have been questioningChina's "preparedness" of making the change.
CGTN: China's dynamic zero-COVID policy sets the foundation for reopening
BEIJING, Jan. 5, 2023 /PRNewswire/ -- China has adjusted its response to COVID-19 prevention and control in recent weeks. It announced it will downgrade COVID-19 management from Class A to Class B infectious disease while resuming passport, visa issuance and easing border-entry policies starting ...
China's optimization of control measures lays solid foundation for COVID-19 response
BEIJING, Jan. 4, 2023 /PRNewswire/ -- A report from People's Daily: Local authorities and relevant departments inChina have been making unremitting efforts recently to ensure the supply of medical resources, satisfy the demand for medicines and focus on the prevention and treatment of high-risk g...
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava inChina in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership ...
CGTN: China monitors coronavirus mutations to adjust COVID-19 response
BEIJING, Jan. 3, 2023 /PRNewswire/ -- With China loosening its COVID-19 restrictions, some experts have expressed concern thatChina's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating. "It is a worry," said CNN, citing William Schaffner, professor at the Divisi...
CGTN: Xi Jinping salutes ordinary people's extraordinary efforts in New Year Address
BEIJING, Jan. 1, 2023 /PRNewswire/ -- From medical professionals to delivery men and women, from community workers to next-door neighbors, ordinary Chinese people are doing their best and lending a hand to help others cope with the latest waves of COVID-19 infections in the country. &amp...
CGTN:How do emergency wards in China cope with increasing COVID patients?
BEIJING, Jan. 3, 2023 /PRNewswire/ -- Ninety-year-old Qu Fucheng was waiting
for his COVID-19 treatment in Wuhan Zhongnan Hospital when his son realized how
crowded the emergency department was.
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
GAITHERSBURG, Md., Dec. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CI...
Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19
* GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load;...
CGTN: Vitality under COVID-19: China's smart ports aid increased throughput
BEIJING, Dec. 29, 2022 /PRNewswire/ -- China's Qingdao Port, a subsidiary of Shandong Port Group and the second-largest foreign trade port in eastChina's Shandong Province, has seen an increase in anchorage rotations of very large container ships, according to China Media Group. The port has han...
CGTN: Vitality under COVID-19: China gears up for medical supplies
BEIJING, Dec. 28, 2022 /PRNewswire/ -- China has made efforts to ensure the medical supplies needed for COVID-19 prevention and control after it loosened its epidemic measures in early December, which was followed by an increase in infections and surging demand for medicines. The country's Natio...
Brii Biosciences Provides Update on Strategic Clinical Development Progress
Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...
China to downgrade COVID-19 management to Class B
BEIJING, Dec. 27, 2022 /PRNewswire/ -- A report from People's Daily: China will downgrade management of COVID-19 to Class B and cancel quarantine requirements on inbound travelers fromJan. 8, 2023, China's top health authority announced recently. In a statement released late Monday, the National...
Hetero's 'Nirmacom' is world's first generic version of COVID-19 oral drug 'PAXLOVID' to receive WHO Prequalification
* Hetero's 'Nirmacom' (Nirmatrelvir), a generic version of Pfizer's COVID-19 oral antiviral drug 'PAXLOVID' is co-packaged with ritonavir tablets * With the launch of Nirmacom, Hetero aims to expand access of the ground-breaking antiviral in 95 LMICs including India HYDERABAD, India, Dec. 27, ...
China actively optimizes COVID-19 response measures to better prepare for challenges
BEIJING, Dec. 26, 2022 /PRNewswire/ -- As multiple regions in China have seen surging COVID-19 infections, local governments are taking swift and precise measures to prevent severe cases, protect people's health, and build a barrier against the epidemic. These measures include providing timely m...
CGTN: 'New Approaches': How China stepped up its COVID-19 treatments
BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helpedChina evade...
Week's Top Stories
Most Reposted
iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00To jointly build equal, orderly multipolar world
[Picked up by 247 media titles]
2024-03-28 14:27